S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

AB

Ab Science (AB)

Ab Science

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:EU:AB

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
05/07/2024	11:05AM	GlobeNewswire Inc.	AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	EU:AB	Ab Science
05/07/2024	11:05AM	GlobeNewswire Inc.	AB Science:	EU:AB	Ab Science
05/07/2024	11:05AM	GlobeNewswire Inc.	AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	EU:AB	Ab Science
05/02/2024	12:14PM	GlobeNewswire Inc.	AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB Science	EU:AB	Ab Science
05/02/2024	12:14PM	GlobeNewswire Inc.	AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science	EU:AB	Ab Science
05/02/2024	12:14PM	GlobeNewswire Inc.	AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science	EU:AB	Ab Science
04/30/2024	11:56AM	GlobeNewswire Inc.	AB Science announces a slight delay in the publication of its 2023 annual financial report	EU:AB	Ab Science
04/30/2024	11:56AM	GlobeNewswire Inc.	AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023	EU:AB	Ab Science
04/30/2024	11:56AM	GlobeNewswire Inc.	AB Science announces a slight delay in the publication of its 2023 annual financial report	EU:AB	Ab Science
04/03/2024	11:08AM	GlobeNewswire Inc.	AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS	EU:AB	Ab Science
04/03/2024	11:08AM	GlobeNewswire Inc.	AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA	EU:AB	Ab Science
03/13/2024	6:58AM	GlobeNewswire Inc.	AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune	EU:AB	Ab Science
03/13/2024	6:58AM	GlobeNewswire Inc.	AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease	EU:AB	Ab Science
03/13/2024	6:58AM	GlobeNewswire Inc.	AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease	EU:AB	Ab Science
03/07/2024	8:20AM	GlobeNewswire Inc.	AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB Science	EU:AB	Ab Science
03/07/2024	8:20AM	GlobeNewswire Inc.	AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development	EU:AB	Ab Science
03/07/2024	8:20AM	GlobeNewswire Inc.	AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development	EU:AB	Ab Science
03/06/2024	1:21PM	GlobeNewswire Inc.	AB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre part	EU:AB	Ab Science
03/06/2024	1:21PM	GlobeNewswire Inc.	AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company	EU:AB	Ab Science
03/06/2024	1:21PM	GlobeNewswire Inc.	AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company	EU:AB	Ab Science
03/01/2024	11:07AM	GlobeNewswire Inc.	AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET	EU:AB	Ab Science
03/01/2024	11:07AM	GlobeNewswire Inc.	AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30	EU:AB	Ab Science
03/01/2024	11:07AM	GlobeNewswire Inc.	AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET	EU:AB	Ab Science
02/29/2024	4:49AM	GlobeNewswire Inc.	AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30	EU:AB	Ab Science
02/29/2024	4:49AM	GlobeNewswire Inc.	AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET	EU:AB	Ab Science
02/29/2024	4:49AM	GlobeNewswire Inc.	AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET	EU:AB	Ab Science
02/26/2024	11:32AM	GlobeNewswire Inc.	AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS	EU:AB	Ab Science
02/26/2024	11:32AM	GlobeNewswire Inc.	AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS	EU:AB	Ab Science
02/26/2024	11:32AM	GlobeNewswire Inc.	AB Science annonce que Santé Canada a émis un Avis de Non-Conformité-Retrait (ANC-R) pour le masitinib dans la SLA	EU:AB	Ab Science
01/26/2024	11:01AM	GlobeNewswire Inc.	AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency	EU:AB	Ab Science

Showing the most relevant articles for your search:EU:AB

1 2 3 4 5 6 7 8 9 10 Next >>

ProText Mobility (PK)

Emergent Health (PK)

Music Licensing (PK)

NaturalShrimp (QB)

Ronn Motor (PK)

Brookmount Explorations (PK)

Yuenglings Ice Cream (PK)

Clean Vision (QB)

Elite Pharmaceuticals (QB)

Globestar Therapeutics (PK)

Anavex Life Sciences

Innovation Pharmaceuticals (CE)

ERHC Energy (CE)

Buildablock (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions